You are in the accessibility menu

Please use this identifier to cite or link to this item: http://acervodigital.unesp.br/handle/11449/131469
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSouza, Paula C. de-
dc.contributor.authorMaia, Pedro I. S.-
dc.contributor.authorBarros, Heloisa B. de-
dc.contributor.authorLeite, Clarice Q. F.-
dc.contributor.authorDeflon, Victor M.-
dc.contributor.authorPavan, Fernando R.-
dc.date.accessioned2015-12-07T15:36:01Z-
dc.date.accessioned2016-10-25T21:23:36Z-
dc.date.available2015-12-07T15:36:01Z-
dc.date.available2016-10-25T21:23:36Z-
dc.date.issued2015-
dc.identifierhttp://dx.doi.org/10.2174/1574884708666131229124748-
dc.identifier.citationCurrent Clinical Pharmacology, v. 10, n. 1, p. 66-72, 2015.-
dc.identifier.issn2212-3938-
dc.identifier.urihttp://hdl.handle.net/11449/131469-
dc.identifier.urihttp://acervodigital.unesp.br/handle/11449/131469-
dc.description.abstractTuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis (MTB) and still an important public health problem worldwide. Some factors like the emergence of multidrug resistant (MDR) and extensively drug-resistant (XDR) strains make urgent the research of new active compounds. Searching for new inorganic compounds against TB, three new dioxovanadium(V) complexes were obtained upon reaction of [VO(acac)2] with hydrazone and thiosemicarbazone ligands derived from di-2-pyridyl ketone. Spectroscopic studies and X-ray crystallography revealed asymmetrically oxo bridged binuclear complexes of the type [{VO(L(1,2))}2(μ-O)2], involving the hydrazone ligands, while a mononuclear square pyramidal complex of the type [VO2(L(3))] was formed with the thiosemicarbazone ligand. The compounds were tested against M. tuberculosis and three of them, with MICs values between 2.00 and 3.76 μM were considered promising for TB treatment. Such MIC values are comparable or better than those found for some drugs currently used in TB treatment.en
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
dc.format.extent66-72-
dc.language.isoeng-
dc.publisherBentham Science Publishers-
dc.sourcePubMed-
dc.subjectDioxovanadium(V)en
dc.subjectHydrazoneen
dc.subjectMycobacterium tuberculosisen
dc.subjectNew antituberculosis compoundsen
dc.subjectThiosemicarbazoneen
dc.titleVanadium complexes with hydrazone or thiosemicarbazone ligands as potential anti-mycobacterium tuberculosis agentsen
dc.typeoutro-
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)-
dc.contributor.institutionUniversidade de São Paulo (USP)-
dc.description.affiliationFaculdade de Ciências Farmacêuticas (FCFAR), Universidade Estadual Paulista (UNESP), Araraquara, SP, Brasil-
dc.description.affiliationInstituto de Química de São Carlos, Universidade de São Paulo (USP), São Carlos, SP, Brasil-
dc.description.affiliationUnespFaculdade de Ciências Farmacêuticas (FCFAR), Universidade Estadual Paulista (UNESP), Araraquara, SP, Brasil-
dc.description.sponsorshipIdCNPq: 406827/2012-5-
dc.description.sponsorshipIdFAPESP: 2009/54011-8-
dc.description.sponsorshipIdFAPESP: 2013/14957-5-
dc.description.sponsorshipIdFAPESP: 2014/11586-9-
dc.identifier.doi10.2174/1574884708666131229124748-
dc.rights.accessRightsAcesso restrito-
dc.relation.ispartofCurrent Clinical Pharmacology-
dc.identifier.pubmed24433444-
Appears in Collections:Artigos, TCCs, Teses e Dissertações da Unesp

There are no files associated with this item.
 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.